Insulin-like growth factors (IGFs) regulate breast cancer cell proliferation, protect cells from apoptosis, and enhance metastasis. In this study, we examined the IGF signaling pathway in two breast cancer cell lines selected for metastatic behavior. LCC6 was selected for growth as an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P). The MDA-231BO cell line was derived from osseous metastases that formed after intracardiac injection of the MDA-MB-231 cell line in athymic mice. Compared to the parental cell lines, IGF-I treatment enhanced IRS-2 phosphorylation over IRS-1 in the metastatic variants. IGF-I stimulated cell migration in the variant cells, but not in the parental cells. To determine the role for IRS-2 in IGF-mediated motility, we transfected MDA-231BO cells with an anti-sense IRS-2 construct. Transfected cells had decreased levels of IRS-2 with diminished IGFmediated motility and anchorage independent growth when compared to control cells. However, adherence to ®bronectin was enhanced in the transfected cells compared to MDA-231BO cells. Our data show that breast cancer cells selected for metastatic behavior in vivo have increased IRS-2 activation and signaling. In these cells, IGF-I enhances cell adhesion and motility suggesting that IRS-2 may mediate these aspects of the malignant phenotype. Oncogene (2001) 20, 7318 ± 7325.
Introduction
Metastatic breast cancer is essentially an incurable disease. The speci®c sequential steps that lead to metastatic disease have become increasingly clear: vascularization of the tumor, invasion into stroma, embolization into the circulation, arrest in capillary beds and extravasation. Recent ®ndings have helped to reveal that each of these steps is under the control of dierent growth factors, including the insulin-like growth factors (IGFs). The mitogenicity of IGF-I is widely recognized, however evidence has also demonstrated the involvement of IGF-I in metastatic steps. IGF-I has been shown to induce migration in melanoma cells (Stracke et al., 1989) , pancreatic carcinoma cells (Klemke et al., 1994) , lung carcinoma cells (Long et al., 1998) and breast cancer cells (Doerr and Jones, 1996; Dunn et al., 1998) . Metastatic potential of the M-27 carcinoma cell line was augmented by the expression of the IGFR1 (Long et al., 1998) . Furthermore, interruption of IGFR1 expression by anti-sense oligonucleotides (Long et al., 1995) or inhibition of IGF interaction with its receptor (Dunn et al., 1998) can inhibit some of the processes involved in cell metastasis. These studies show that IGFR1 activation is an important factor in breast cancer metastasis and that targeting receptor function may inhibit the metastatic potential of the cell.
We have previously shown that insulin-receptor substrate-1 (IRS-1) is involved in IGF-mediated proliferation (Jackson et al., 1998) . However, it is not clear which IGFR1 signaling molecules and pathways are activated in the metastatic process. To investigate this problem, we utilized two breast cancer cell lines: MDA-MB-231 and MDA-MB-435, and two highly metastatic variants of these cells selected in vivo from a bone metastasis (MDA-231BO) and ascites growth (LCC6), respectively (Leonessa et al., 1996; Yoneda et al., 2001) . We found that both metastatic variants had enhanced tyrosine phosphorylation of IRS-2 after IGF-I treatment compared to parental cell lines. The MDA-231BO variant achieved enhanced IRS-2 signaling by increasing IGFR1 expression, the LCC6 variant by increasing IRS-2 protein levels. IGF-I-induced motility was increased in both metastatic variants when compared to their respective parental cell lines. To determine if IRS-2 was directly involved in IGFmediated migration, we transfected MDA-231BO cells with an anti-sense IRS-2 vector. Diminished IRS-2 expression resulted in a loss of IGF-mediated motility and enhanced adhesion to ®bronectin. These data suggest that IGF-I can stimulate cell motility through IRS-2 by in¯uencing cell adhesion. Furthermore, enhancement of this signaling pathway may augment some of the processes involved in metastasis.
Results

Metastatic variants have increased tyrosine phosphorylation of IRS-2 after IGF-I treatment
Numerous studies implicate IGF-I and its receptor in metastasis. Because of this, we examined IGF-I signaling in two breast cancer cell lines, MDA-MB-231 and MDA-MB-435, and their two derived metastatic variants, MDA-231BO and LCC6, respectively. Initially, we stimulated cell monolayers with IGF-I and immunoblotted for antiphosphotyrosine to determine if any dierences in activated proteins could be detected. After IGF-I treatment, we found there was greater tyrosine phosphorylation of an approximately 185 kDa protein in both the MDA-231BO variant compared to its parental MDA-MB-231 cell line ( In order to determine the identity of this protein, cell lysates were immunoprecipitated with antibodies speci®c for IRS-1 or IRS-2 and immunoblotted for antiphosphotyrosine. We found low levels of IRS-1 However, IRS-2 phosphorylation was markedly increased in both metastatic variant cell lines when compared to the parental cell lines (Figure 1a ,b, compare lane 8 versus lane 12 for both panels). Thus, the increased phosphotyrosine containing protein of 185 kDa observed for each metastatic variant was IRS-2.
Expression of signaling proteins in parental cells and metastatic variants
Increased activation of IRS-2 could be accomplished by either increasing the phosphotyrosine content of the same amount of protein, or increasing the total amount of protein without altering the level of tyrosine phosphorylation per IRS molecule. We performed immunoblots to determine which of these mechanisms accounted for the increased IRS-2 activation in the metastatic variants. IRS-1 immunoblot showed that levels were decreased in the MDA-231BO variant compared to MDA-MB-231 ( Figure 2a ) and not signi®cantly dierent in the LCC6 variant when compared to MDA-MB-435 parental. IRS-2 immunoblot showed that IRS-2 levels were greatly increased in LCC6 cells compared to the MDA-MB-435 parental cell line (Figure 2a ). However, IRS-2 levels were not signi®cantly dierent in MDA-231BO compared to MDA-MB-231.
Ribonuclease protection assay showed that steady state levels of IRS-2 mRNA were similar between both parental and variant cells (data not shown). Figure 2b shows that IGFR1 levels were increased in the MDA-231BO cells compared to its parental MDA-MB-231 cell line. Levels of IGFR1 were dicult to detect in LCC6 and MDA-MB-435 cells, but no apparent change was noted (data not shown). Thus, increased IRS-2 activation observed in Figure 1 was due to increased levels of IRS-2 protein in LCC6. In MDA-231BO cells, increased IGFR1 expression resulted in increased phosphorylation of IRS-2 compared to the parental cell line. Figure 2a shows that two key signaling molecules downstream of IRS-2, p85 PI3 kinase and MAP kinase were not signi®cantly changed in the two metastatic variant cell lines.
Cell migration in parental cells and metastatic variants
Migration of cells across a porous membrane can be used to identify factors that contribute to metastatic potential. We found that IGF-I stimulated migration in LCC6 ( Figure 3a ) and MDA-231BO ( Figure 3b ). Under our test conditions, migration was not stimulated by IGF-I in either of the parental cell lines. IGF-I, which stimulates cell proliferation in MCF-7 cells via IRS-1 (Jackson and Yee, 1999) , did not enhance migration ( Figure 3c ).
Downregulation of IRS-2 expression decreases IGF-mediated motility
Our data show that increased IRS-2 phosphorylation was associated with enhanced IGF-mediated motility in two cell lines selected for enhanced metastatic behavior. To determine if IRS-2 is required for IGFmediated motility, we expressed an anti-sense IRS-2 vector in MDA-231BO cells. The expression construct contained a fragment of the IRS-2 cDNA linked to green¯uorescent protein via an internal ribosome entry site sequence. Stable transfection and selection of individual clones often results in cells with signi®cant heterogeneity due to clonal variation. Since our vector contained GFP, we decided to select positive cells bȳ ow cytometry and pool transfectants to avoid this problem. Expression of the constructs was also evaluated by GFP immunoblot (data not shown). Figure 4a shows that levels of IRS-2 were decreased in the pooled anti-sense transfected cells. However, this level of decreased IRS-2 expression did not substantially diminish the level of phospho-IRS-2 after IGF-I treatment. Figure 4b shows that immunoprecipitation with either IRS-1 or IRS-2 followed by anti-phosphotyrosine immunoblotting shows little dierence in parent (231BO), sense, or anti-sense cells. We also examined signaling pathways downstream of IRS adaptor proteins in the transfected cells. We were unable to show changes in phospho-MAPK or phospho-Akt in the anti-sense transfected cells (data not shown).
Effect of decreased IRS-2 expression on migration and adhesion
We next examined the eect of decreased IRS-2 expression on cell migration. In Figure 5a the results are expressed as per cent of untreated cells. In the cells transfected with the anti-sense vector, there is a clear reduction in IGF-I mediated cell migration. However, we noticed that anti-sense cells seemed to have a higher basal migration rate when compared to parent or sense-transfected cells. Figure 5b shows the results presented as the actual number of migrating cells. Thus, anti-sense cells were not responsive to IGF-I because their basal rate of migration appeared to be enhanced.
Migration involves both the formation and release of adhesive complexes (Lauenburger and Horwitz, 1996) . Since our migration experiments were done in the presence of ®bronectin, it was possible that the IGF-stimulated migration was due to changes in cell adhesion to ®bronectin. To directly test this hypothesis, we examined adhesion of breast cancer cells to ®bronectin and type I collagen with and without IGF-I treatment. On ®bronectin, IGF-I increased adhesion of the metastatic variants (231BO) and sense transfected cells (Figure 6a ). In contrast, the parental cells (231) and the anti-sense transfected cells had higher adhesive rates to ®bronectin and were not in¯uenced by IGF-I. MCF-7 cells were poorly adherent to ®bronectin and adhesiveness did not increase after IGF-I treatment. When cells were allowed to adhere to type I collagen, IGF-I treatment did not alter cell adhesion of the metastatic variant, sense, or anti-sense transfected cells (Figure 6b ). These data show that the metastatic variant cells were less adherent to ®bronec-tin compared to the parental MDA-231 cells. In these metastatic variants, IGF-I enhanced cell adhesion and migration in ®bronectin containing media. 
Effect of decreased IRS-2 expression on anchorage independent growth
To determine if diminished IRS-2 expression aected another measure of metastatic potential, we examined the eects of IGF-I on anchorage independent growth in MDA-231, MDA-231BO and the transfected cells after stimulation with IGF-I. Since we were primarily interested in determining if IGF responses were blunted, the results are presented as per cent of unstimulated colony growth for each cell line. Figure 7 shows that colony formation of MDA-231 cells was not enhanced by IGF-I as previously shown (Yoneda et al., 2001) . In contrast, IGF-I stimulated colony formation in the MDA-231BO variant cell line. When IRS-2 is diminished by anti-sense IRS-2 expression, response to IGF-I was lost. Control cells transfected with the IRS-2 sense construct maintained responsiveness to IGF-I.
Discussion
Breast cancer becomes a lethal disease after it metastasizes and proliferates at distant sites. Therefore, identifying the pathways that regulate cell metastasis is highly relevant. In many cell types, including human breast cancer, IGF-I signaling has been shown to mediate metastasis in vivo as well as in vitro markers of metastasis like migration, motility, and invasion. The bulk of data have shown that IGFR1 can participate in signaling events involved in metastasis of breast cancer cells. By overexpressing IGFR1, Guvakova and Surmacz (1999) were able to use IGF-I to activate signaling pathways that resulted in actin cytoskeletal reorganization. IGF-I has also been shown to stimulate invasion through collagen IV in the two parental breast cancer cell lines used in this study, MDA-MB-231 and MDA-MB-435 (Doerr and Jones, 1996; Dunn et al., 1998) . In contrast, we did not ®nd IGF-mediated cell migration in these parental cells. In our experiments, we used ®bronectin containing medium, but left the plastic support uncoated. Thus, our studies were performed under less favorable conditions for the cells. Since speci®c substrates play an important role in regulating adhesion and subsequent signaling, our studies were designed to address only the eects on cell migration.
Less data exist on the downstream pathways involved in mediating these events. Recent data suggests that IRS molecules are involved in motility and migration of cancer cells (Reiss et al., 2001; Shaw, 2001) . In this study, we show that increased IRS-2 signaling was a common factor in two breast cancer cell lines selected in vivo for their metastatic behavior. IGFR1 signaling may have played a part in the metastatic behavior of these cell lines and increased IRS-2 signaling was actually selected for in the metastatic process. However, increased IRS-2 is not necessarily the only signaling molecule changed in these cell lines. Indeed, we found that MDA-231BO cells had an increased expression of p66 Shc. Epidermal growth factor, but not IGF-I, was able to activate p66 Shc, therefore the elevated levels of p66 are not likely to directly contribute to IGF-I signaling (Jackson et al., 2000) . Shc was not activated by IGF-I in the MDA-MB-435/LCC6 cell lines (data not shown).
Some studies have shown that primary human breast cancer cells with decreased adhesion to matrix proteins are more likely to metastasize to regional lymph nodes (Gui et al., 1997; Yu et al., 1998) . It has been suggested that loss of integrin expression occurs as transformed mammary epithelial cells become more poorly dierentiated (Zutter et al., 1998) . Our results are compatible with these ®ndings; the cell line selected for enhanced metastasis has a decreased ability to adhere to ®bronectin. In the case of the MDA-231 cell line, selection for increased bone metastasis in vivo resulted in a cell (MDA-231BO) that had decreased adhesion, enhanced motility, enhanced IGF responsiveness and increased IRS-2 activation in response to IGF-I. In the absence of IGF-I, MDA-231BO cells were less adherent to ®bronectin than the parental cell line. IGF-I treatment resulted in enhanced adherence of MDA-231BO, but the parent cell line was unaected. This increased adhesion in the presence of IGF-I resulted in enhanced migration in the Boyden chamber assay. Since cells must attach in order to migrate in this assay, IGF-I stimulated cell motility under these conditions. Furthermore, IGF-I enhances anchorage independent growth in MDA-231BO cells providing further evidence that during the generation of more metastatic variants of MDA-231 cells, enhanced responsiveness to the IGFs via IRS-2 was selected.
Several model systems have shown an interaction between cell adhesion and the IGF signaling pathway. In breast cancer cells, Guvakova and Surmacz (1997) have shown that IGFR1 enhances adherence via Ecadherin complexes. In colon cancer cells, both E- cadherin and integrins may cooperate with IGFR1 to enhance migration (Andre et al., 1999) . Several lines of evidence suggest that direct interactions between integrin and IGFR1 signaling pathways exist. Vuori and Ruolahti (1994) showed that IRS-1 and the aVb3 vitronectin receptor may cooperate. In cancer cells, direct interactions with the a5b1 integrin and IRS molecules have been demonstrated (Reiss et al., 2001) . IRS-1 mRNA expression appears to be regulated by integrin signaling (Lebrun et al., 2000) . Clemmons et al. (1999) have shown that the aVb3 integrin receptor is involved in IGF-I stimulated smooth muscle cell migration and replication. In mammary epithelial cells, it has been shown that activation of IRS-1 by insulin or IGF-I requires contact of cells with the basement membrane (Farrelly et al., 1999; Lee and Streuli, 1999) .
Our data are consistent with the concept that IGF, cell adhesion, and tumorigenesis are linked. IGF-I enhanced cell motility and increased IRS-2 phosphorylation in two independently derived metastatic variants of two dierent breast cancer cell lines. This enhanced IRS-2 signaling was not only correlated with increased metastatic potential, but also with enhanced IGF-I induced migration, adhesion, and anchorageindependent growth. Contrary to our expectations, we did not show that decreased IRS-2 expression resulted in decreased IRS-2 tyrosine phosphorylation in the MDA-231BO anti-sense cell line. However, it is clear that diminished levels of IRS-2 signi®cantly aected the cell's response to IGF-I. Further study will be required to determine how IRS-2 exerts these eects. It is possible that IRS-2 serves as a link between integrin and IGFR1 signaling and that total, but not phosphorylated, levels of IRS-2 mediate this interaction. Alternatively, the subcellular location of IRS-2 may also be important in mediating IGF eects. It has been suggested that association between IRS proteins and speci®c membrane domains may in¯uence insulin's ability to phosphorylate PI3 kinase . It is also possible that serine or threonine phosphorylation sites may mediate the motility response to IGF-I. We, and others, have shown that inhibition of serine/ threonine kinases can in¯uence IRS action (Lee et al., 2000; Smith et al., 1995; Tanti et al., 1994) . Clearly, total levels of IRS-2 in¯uence breast cancer cell biology as we show that cell adhesion to ®bronectin is markedly aected by decreasing IRS-2 levels, even in the absence of IGF-I. IRS-2 appears to regulate IGF dependent and independent eects in breast cancer cells.
Our previous results have shown that IRS-1 is the predominant substrate activated in IGF-I mediated cell proliferation (Jackson et al., 1998) and protection from chemotherapy-induced apoptosis (Gooch et al., 1999) . Thus, data exist showing that the IGFs participate in all aspects of the malignant phenotype; proliferation, protection from apoptosis, and cell migration. While it is clear that IGFR1 is responsible for stimulating these phenotypes, the precise response to IGF stimulation may be dependent on the speci®c IRS species activated.
Selection of signaling pathways distal to IGFR1 during the progression of malignant cells may account for these dierential responses to IGFs.
Materials and methods
Reagents
All chemicals and reagents were purchased from Sigma (St. Louis, MO, USA) unless noted otherwise. Alpha Diagnostics, Inc (San Antonio, TX, USA) produced IRS-1 rabbit antiserum with peptide sequence YASINFQKPEDRQ and has been described (Jackson and Yee, 1999) . IRS-2, MAP kinase, P-85 PI3 kinase antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA). RC-20 antiphosphotyrosine was purchased from Transduction Labs (Lexington, KY, USA). aIR3 antibody to IGFR1 used in immunoprecipitation was from Oncogene Science (Cambridge, MA, USA), IGFR1 antibody (sc-713) used for immunoblot was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase (HRP) linked antirabbit antibody and rainbow molecular weight markers were from Amersham Pharmacia Biotech. IGF-I was from Gro Pep (Adelaide, Australia). Acrylamide/Bis was from BioRad (Hercules, CA, USA). MDA-MB-435 Parental and LCC6 cells were a gift from Drs Robert Clarke and Nils BruÈ nner (Lombardi Cancer Center, Washington, DC, USA). LCC6 are a variant of the MDA-MB-435 parental cell line selected to grow as ascites tumors in athymic mice (Leonessa et al., 1996) . MDA-MB-231 cells were originally from American Type Culture Collection (Rockville, MD, USA). MDA-231BO metastatic variant was created in the lab of Dr Toshiyuki Yoneda (San Antonio, TX, USA) as described (Yoneda et al., 2001) . Brie¯y, after intracardiac injection of MDA-MB-231 cells into athymic mouse, bone metastases that formed were established in vitro after 11 serial passages in vivo.
Cell stimulation and lysis
For stimulation experiments, cells were cultured in Dulbecco's Modi®cation of Eagle's Medium (DMEM, Cellgro, Herndon, VA, USA) with 5% fetal calf serum (Summit Biotech, Fort Collins, CO, USA) and 10 nM insulin until 70% con¯uent, then washed twice with phosphate buered saline (PBS; Bio¯uids, Rockville, MD, USA). Medium was then changed to serum free medium (SFM, previously described (Cullen et al., 1990 )) for 24 h, then replaced with SFM plus 5 nM IGF-I for 10 min. Cells were washed twice in ice cold PBS and lysed with 500 ml per 10 cm plate with TNESV buer (50 mM ± Tris-pH 7.4, 1% NP-40, 2 mM EDTA, 100 mM NaC1, 10 mM sodium orthovanadate, 1 mM PMSF, 20 mg/ml leupeptin, 20 mg/ml aprotinin). Protein concentration of the cleared lysates was determined by the copper-bicinchoninic acid method with a Pierce Laboratory kit (Rockford, IL, USA).
Immunoprecipitations
All steps were performed on a platform rocker at 48C. Equal amounts of protein (500 mg) were ®rst pre-cleared with 25 ml of protein A agarose (Pierce, Rockford, IL, USA) for 30 min, then incubated with the indicated antibody overnight at concentrations according to the manufacturer's instructions, or 1 ml IRS-1 antiserum per 100 mg of cellular protein.
Twenty-®ve ml of protein A agarose was then added for 4 h, followed by three washes with TNESV buer. Beads were resuspended in 26 Laemmli loading buer with 30 mg/ml dithiothreitol, boiled, and separated by SDS ± PAGE (Jackson and Yee, 1999).
Immunoblotting
After SDS ± PAGE proteins were transferred overnight to nitrocellulose membranes (BioRad, Hercules, CA, USA). All blotting steps were carried out at room temperature with gentle rocking. The membranes were blocked in 5% non-fat dry milk in Tris-buered saline-Tween 20 (TBST: 0.15 M NaCl, 0.01 M Tris HCl ± pH 7.4, 0.05% Tween 20). For antiphosphotyrosine blotting with RC-20, membranes were washed ®ve times over 30 min with TBST after blocking, incubated with a 1000 : 1 dilution in TBST for 2 h, washed, then chemiluminescence was performed as described below. IRS-1, IRS-2, MAPK, P-85 PI3K blotting was performed with antibodies diluted 1000 :1 and IGFR1 was diluted 200 : 1 in blocking buer. After a 1 h incubation in primary antibody, blots were washed then incubated with a 2000 : 1 dilution of HRP linked anti-rabbit secondary antibody in blocking buer for 1 h, followed by further washing. Enhanced chemiluminescence was performed according to manufacturer's instructions (Pierce, Rockford, IL, USA). Densitometry was performed by scanning the radiographs (ScanJet Ilcx, Hewlett-Packard) then analysing the bands with ImageTool version 2.0 software (University of Texas Health Science Center at San Antonio).
Cell motility assay
Cell migration was measured by two dierent culture systems. The initial experiments used cell inserts with 8 mm pores (Collaborative Biomedical Products, Bedford, MA, USA). Subsequent experiments used 10 well chambers (Neuro Probe, Inc., Gaithersburg, MD, USA) with 12 mm pores. We found that both systems produced identical results (data not shown). SFM (0.4 ml) with or without IGF (5 nM) was placed in the bottom wells of the chamber. A polycarbonate polyvinylpyrrolidone-free ®lter (12 mm pore size) was placed above this. After detachment in PBS-EDTA, cells were washed twice with PBS, then resuspended in SFM, and 0.3 ml cell suspension (5610 5 cells/ml) was added to the top wells of the chamber above the ®lter. At the end of incubation, cells remaining on the topside of the ®lter were removed with cotton swabs. The ®lter was then removed from the chamber and the cells that had migrated to the underside of the ®lter were ®xed and stained in HEMA3 (Fisher). The ®lter was then mounted on to a glass microscope slide and cells were counted in 10 dierent areas using a light microscope.
